Among patients with active cancers associated with a lower risk of bleeding on an oral factor Xa inhibitor and experiencing an acute VTE, rivaroxaban had similar effectiveness and safety to apixaban at 3 months and 6 months. The gene discussed is F10; the disease is cancer.